Global Proteomics Analysis of S-023-0996 Treatment in Human Breast Cancer Cell line MDA-MB-231

ABSTRACT: To elucidate the mechanism underlying the anticancer activity of S-023-0996, global proteomic analysis was performed in human breast cancer cells. Mass spectrometry-based proteomic profiling was carried out in MDA-MB-231 cells following treatment with four experimental groups: Tazemetostat (Taz), Gefitinib (Gef), a combination of Tazemetostat and Gefitinib (Taz + Gef), and S-023-0996 (41a), along with a vehicle control (Control). The proteomic profiles of each treatment group were compared with that of the control, and the differential protein expression specific to S-023-0996 was subsequently analysed to elucidate the molecular mechanisms underlying its superior anticancer activity.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Mda-mb-231 Cell

SUBMITTER: Dipak Datta  

LAB HEAD: Dr. Dipak Datta

PROVIDER: PXD080173 | Pride | 2026-09-03

REPOSITORIES: Pride